APA (7th ed.) Citation

J, G., K, B., K, B., KJ, C., B, G., M, J., . . . V, S. (2025). Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: Recommendations from the European Immunogenicity Platform. Frontiers in immunology, 16, 1581153. https://doi.org/10.3389/fimmu.2025.1581153

Chicago Style (17th ed.) Citation

J, Grudzinska-Goebel, et al. "Immunogenicity Risk Assessment for Tailored Mitigation and Monitoring of Biotherapeutics During Development: Recommendations from the European Immunogenicity Platform." Frontiers in Immunology 16 (2025): 1581153. https://doi.org/10.3389/fimmu.2025.1581153.

MLA (9th ed.) Citation

J, Grudzinska-Goebel, et al. "Immunogenicity Risk Assessment for Tailored Mitigation and Monitoring of Biotherapeutics During Development: Recommendations from the European Immunogenicity Platform." Frontiers in Immunology, vol. 16, 2025, p. 1581153, https://doi.org/10.3389/fimmu.2025.1581153.